Pfizer, 23andMe team up to study bowel disease

Published



WASHINGTON (AP) — Pfizer Inc. is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.

Under the agreement, Silicon Valley-based 23andMe will map the DNA of 10,000 patients who have forms of the disease, which include Crohn’s disease and ulcerative colitis. Patients will submit saliva samples using 23andMe’s at-home collection kit and then fill out online questionnaires about their disease and symptoms.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.